Inspire Medical Systems, Inc. (NYSE:INSP) Shares Sold by Rhumbline Advisers

Rhumbline Advisers lowered its position in Inspire Medical Systems, Inc. (NYSE:INSP) by 2.9% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 71,535 shares of the company’s stock after selling 2,115 shares during the quarter. Rhumbline Advisers owned about 0.24% of Inspire Medical Systems worth $11,394,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently added to or reduced their stakes in the company. Smartleaf Asset Management LLC increased its stake in shares of Inspire Medical Systems by 178.9% during the fourth quarter. Smartleaf Asset Management LLC now owns 357 shares of the company’s stock valued at $66,000 after acquiring an additional 229 shares during the period. Mutual of America Capital Management LLC grew its position in Inspire Medical Systems by 1.2% in the fourth quarter. Mutual of America Capital Management LLC now owns 4,540 shares of the company’s stock worth $842,000 after buying an additional 55 shares during the last quarter. Jones Financial Companies Lllp grew its position in Inspire Medical Systems by 11.3% in the fourth quarter. Jones Financial Companies Lllp now owns 2,075 shares of the company’s stock worth $385,000 after buying an additional 210 shares during the last quarter. New York State Teachers Retirement System grew its holdings in shares of Inspire Medical Systems by 13.6% in the 4th quarter. New York State Teachers Retirement System now owns 9,194 shares of the company’s stock worth $1,704,000 after acquiring an additional 1,100 shares during the last quarter. Finally, WCM Investment Management LLC acquired a new position in shares of Inspire Medical Systems in the 4th quarter worth $10,291,000. 94.91% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Inspire Medical Systems

In other Inspire Medical Systems news, Director Shawn Mccormick sold 360 shares of the business’s stock in a transaction that occurred on Friday, May 2nd. The shares were sold at an average price of $160.00, for a total value of $57,600.00. Following the completion of the sale, the director now directly owns 24,046 shares of the company’s stock, valued at $3,847,360. The trade was a 1.48% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. 4.10% of the stock is currently owned by company insiders.

Inspire Medical Systems Stock Up 0.4%

Inspire Medical Systems stock opened at $136.50 on Tuesday. The company’s fifty day simple moving average is $148.64 and its 200-day simple moving average is $171.28. Inspire Medical Systems, Inc. has a 12 month low of $123.00 and a 12 month high of $225.00. The stock has a market cap of $4.03 billion, a P/E ratio of 78.90, a P/E/G ratio of 2.86 and a beta of 1.28.

Inspire Medical Systems (NYSE:INSP) last posted its quarterly earnings results on Monday, May 5th. The company reported $0.10 EPS for the quarter, beating the consensus estimate of ($0.23) by $0.33. Inspire Medical Systems had a net margin of 6.67% and a return on equity of 8.19%. The business had revenue of $201.32 million for the quarter, compared to analysts’ expectations of $194.89 million. During the same period in the previous year, the company posted ($0.34) EPS. Inspire Medical Systems’s revenue was up 22.7% on a year-over-year basis. On average, equities research analysts expect that Inspire Medical Systems, Inc. will post 2.16 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on INSP. Piper Sandler dropped their price target on Inspire Medical Systems from $260.00 to $233.00 and set an “overweight” rating on the stock in a research note on Monday, February 10th. JPMorgan Chase & Co. dropped their target price on shares of Inspire Medical Systems from $235.00 to $195.00 and set an “overweight” rating on the stock in a research report on Tuesday, May 6th. Wells Fargo & Company dropped their target price on shares of Inspire Medical Systems from $195.00 to $174.00 and set an “equal weight” rating on the stock in a research report on Tuesday, May 6th. KeyCorp dropped their target price on shares of Inspire Medical Systems from $234.00 to $216.00 and set an “overweight” rating on the stock in a research report on Monday, April 21st. Finally, Robert W. Baird lifted their price objective on shares of Inspire Medical Systems from $230.00 to $236.00 and gave the stock an “outperform” rating in a research report on Tuesday, May 6th. Three equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $211.91.

Inspire Medical Systems Profile

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.